

[ORIGINAL ARTICLE]

Safety and Efficacy of Endoscopic Removal of Common Bile Duct Stones in Elderly Patients ≥90 Years of Age

Hirokazu Saito¹, Takehiko Koga², Masafumi Sakaguchi², Yoshihiro Kadono², Kentaro Kamikawa², Atsushi Urata², Haruo Imamura², Shuji Tada³, Tatsuyuki Kakuma⁴ and Ikuo Matsushita¹

Abstract:

Objective We examined the safety and efficacy of endoscopic stone removal for choledocholithiasis in elderly patients \geq 90 years of age with native papilla and compared the outcomes with those in patients 75-89 years of age.

Methods This multicenter retrospective study included 569 patients 75-89 years of age and 126 patients \geq 90 years of age who had native papilla and underwent therapeutic endoscopic retrograde cholangiopancreatography (ERCP) for choledocholithiasis at 3 institutions in Japan between April 2012 and March 2018. The main outcomes assessed were the incidence of post-ERCP complications during hospitalization and outcomes of ERCP in patients \geq 90 years of age.

Results Biliary cannulation and subsequent endoscopic sphincterotomy, endoscopic balloon dilation, and endoscopic large balloon dilation were successful in 97.7% of patients 75-89 years of age and in 98.4% of patients \geq 90 years of age. There was no significant difference in the incidence of post-ERCP complications between patients 75-89 years of age and those \geq 90 years of age (7.7% vs. 9.5%, respectively; p=0.47). Although the rate of use of mechanical lithotripter was not significantly different, the rate of complete stone removal in patients \geq 90 years of age was lower than that in patients 75-89 years of age (81.0% vs. 94.9%, respectively; p<0.001). In all cases with incomplete stone removal in both groups, permanent biliary stent placement was successful.

Conclusion ERCP for choledocholithiasis in elderly patients \geq 90 years of age is a safe and effective procedure; however, endoscopists should select appropriate strategies after considering each patient's medical condition and background.

Key words: ERCP, common bile duct stone, elderly patient, oldest-old

(Intern Med 58: 2125-2132, 2019) (DOI: 10.2169/internalmedicine.2546-18)

Introduction

According to the 2017 World Population Prospects report by the United Nations, the global increase in life expectancy is contributing to a progressive increase in the proportion of the elderly population (1). Approximately 5% of all patients with cholecystitis have co-existing common bile duct (CBD) stones; among elderly patients with cholecystitis, this percentage is as high as 10-20% (2). Owing to the higher prevalence of CBD stones in the elderly population, endoscopic stone removal in elderly patients is likely to increase in the future.

Although endoscopic removal of CBD stones using endoscopic retrograde cholangiopancreatography (ERCP) is an effective procedure, it is associated with a high risk of post-

Received: December 18, 2018; Accepted: February 17, 2019; Advance Publication by J-STAGE: April 17, 2019 Correspondence to Dr. Hirokazu Saito, arnestwest@yahoo.co.jp

¹Department of Gastroenterology, Kumamoto Chuo Hospital, Japan, ²Department of Gastroenterology, Saiseikai Kumamoto Hospital, Japan, ³Department of Gastroenterology, Kumamoto City Hospital, Japan and ⁴Department of Biostatics Center, Medical School, Kurume University, Japan



Figure. Flowchart of enrolled patients. EST: endoscopic sphincterotomy, EPBD: endoscopic papillary balloon dilation, EPLBD: endoscopic papillary large balloon dilation

ERCP complications, such as post-ERCP pancreatitis (PEP), cholangitis, bleeding, and perforation, in addition to common endoscopic complications, such as pneumonia (3), which pose serious problems for elderly patients.

In Japan, an age of \geq 75 years is classified as old age, while individuals \geq 90 years of age are classified as oldestold (4). Previous studies have investigated the efficacy and safety of therapeutic ERCP for elderly patients using a cutoff age of 80-85 years (5-8); there have been only a few studies on the efficacy and safety of endoscopic stone removal in elderly patients \geq 90 years of age. Previous studies published in 2000 and 2006 showed that there was no significant difference in the incidence of post-ERCP complications between elderly patients \geq 90 years of age and elderly patients 70-89 years of age. In elderly patients \geq 90 years of age, the rate of complete stone removal was lower, additional ERCP attempts were required to achieve stone clearance, and mechanical lithotripters were used more frequently than in those 70-89 years of age (9, 10).

However, these studies included small populations of elderly patients \geq 90 years of age, and endoscopic papillary large balloon dilation (EPLBD) has become increasingly popular following the publication of these reports. We therefore examined the efficacy and safety of endoscopic stone removal in a large cohort of elderly patients \geq 90 years of age and compared their outcomes with those observed in elderly patients 75-89.

Materials and Methods

Patient selection and study design

Medical records pertaining to patients who had undergone

therapeutic ERCP for choledocholithiasis at three institutions in Japan between 2012 and March 2018 were retrospectively reviewed. The inclusion criteria were as follows: (1) elderly patients \geq 75 years of age with choledocholithiasis; (2) patients with native papilla who underwent endoscopic sphincterotomy (EST), endoscopic papillary balloon dilation (EPBD), or EPLBD; and (3) patients with a normal gastrointestinal tract or Billroth I reconstruction. The exclusion criteria were as follows: (1) patients \leq 74 years of age; (2) history of EST, EPBD, or EPLBD; and (3) history of Billroth II or Roux-en-Y reconstruction. A total of 695 elderly patients \geq 75 years of age (569 elderly patients 75-89 years of age and 126 elderly patients \geq 90 years of age) met the study selection criteria and were included in this study (Figure).

This study was approved by the Institutional Review Boards of each of the participating institutions. Informed consent was obtained from all patients prior to their enrollment.

Outcomes

The primary outcome of this study was the incidence of post-ERCP complications during hospitalization. Secondary outcomes were the frequency of mechanical lithotripter use, the number of successful procedures (complete stone removal or permanent biliary stent placement), and the number of ERCP sessions associated with a successful procedure.

Study definitions

• Trainee endoscopists

Trainee endoscopists were defined as endoscopists who had performed <200 ERCP procedures or who could per-

form only procedures equivalent to Grade 1 with or without assistance, according to the ERCP core curriculum published in 2016 (11).

• Post-ERCP complications

Post-ERCP complications were defined as all complications that occurred after the ERCP procedure and during hospitalization. Post-ERCP complications included PEP, bleeding, perforation, acute cholangitis/cholecystitis, pneumonia, and cardiovascular and cerebrovascular events. Acute cholangitis/cholecystitis was diagnosed and graded based on the Tokyo guidelines 2018 (12). Post-ERCP complications, except for acute cholangitis/cholecystitis, were diagnosed and graded based on a lexicon for endoscopic adverse events (13).

• Incomplete stone removal and successful procedure

Incomplete stone removal was defined as cases with successful cannulation wherein complete stone removal could not be achieved (excluding cases with unsuccessful cannulation). A successful procedure was defined as complete stone removal or permanent biliary stent placement in cases with incomplete stone removal.

Emergency ERCP

Emergency ERCP was defined as ERCP performed within 24 hours of the choledocholithiasis diagnosis.

· Severe medical conditions as the reason for incomplete clearance

Severe medical conditions were defined as the reason for incomplete clearance in cases with an unstable cardiorespiratory condition before ERCP or with a high risk of deterioration of the cardio-respiratory condition during or after ERCP.

Diagnostic procedure

One or more imaging examinations, including computed tomography (CT), magnetic resonance cholangiopancreatography (MRCP), endoscopic ultrasonography (EUS), ultrasonography (US), and cholangiography via percutaneous transhepatic gallbladder drainage tube (PTGBD), were performed for the diagnosis of CBD stones in all patients. In cases not diagnosed by imaging examinations, clinical findings such as abdominal pain, dilated CBD, and/or elevated liver function tests were used to establish the diagnosis. The Tokyo guidelines 2018 were used for the diagnosis and grading of acute cholangitis (12).

Criteria for performing ERCP for choledocholithiasis at our institutions

At our institutions, the criteria for ERCP for choledocholithiasis required patient consent for the procedure, including detailed information regarding post-ERCP complications. Patients could not exhibit respiratory or circulatory dysfunction if they were to undergo ERCP.

Therapeutic procedure

Twenty-five endoscopists were included in this study. Nine of these 25 were trainee endoscopists. ERCP procedures performed by trainee endoscopists were assisted by experienced endoscopists. Side-viewing duodenoscopes (Olympus JF-260, TJF-260V; Olympus Medical Systems, Tokyo, Japan) were used in all patients. Intravenous midazolam and/or pethidine hydrochloride were administered for sedation. The doses of midazolam and pethidine hydrochloride were determined based on the sedation protocol at our institutions.

In patients 75-89 years of age who weighed <70 kg, the doses of midazolam and pethidine hydrochloride were 1 mg and 17.5-35 mg, respectively, while the doses in those who weighed ≥70 kg were 2 mg and 17.5-35 mg, respectively. In patients ≥90 years of age, the doses of midazolam and pethidine hydrochloride were 1 mg and 17.5 mg, respectively, regardless of weight. Scopolamine butylbromide or glucagon was used for duodenal relaxation. After biliary cannulation, EST, EPBD, or EPLBD followed by biliary stent placement or stone removal was performed. EPLBD was indicated for patients with large and/or multiple stones, with CBD dilation, which were difficult to remove by either EST or EPBD. One or more devices, including balloon catheter, basket, and/or a mechanical lithotripter, were used to remove the CBD stones. A permanent biliary stent was placed in patients with a poor performance status, severe medical condition, and multiple and/or large stones that were difficult to remove based on the endoscopist's decision.

Statistical analyses

Between-group differences with respect to the demographic and clinical characteristics, ERCP-related findings and outcomes, the reasons for incomplete stone removal, and complications and severity of ERCP were assessed using the chi-squared test, Fisher's exact test, or t-test, as appropriate. All statistical analyses were performed using R version 3.5.1 (http://www.R-project.org). P values <0.05 were considered indicative of statistically significant differences.

Results

Demographic and clinical characteristics

Demographic and clinical characteristics of the study population are presented in Table 1. Compared to patients 75-89 years of age, significantly more elderly patients ≥ 90 years of age underwent emergency ERCP, had severe acute cholangitis, exhibited a dilated common bile duct (>10 mm), and had a poor performance status (3 or 4). Although not statistically significant, patients ≥90 years of age were more likely to exhibit large stones (>10 mm) and multiple large stones, compared with patients 75-89 years of age.

Diagnostic modality for CBD stones

The imaging modalities used for the diagnosis of CBD stones were MRCP [79/695 (11.4%)], CT [466/695 (67.1%)], US [28/695 (4.0%)], EUS [2/695 (0.3%)], and

	Patients aged 75-89 years (n=569)		Patients aged ≥90 years (n=126)		
	n	%	n	%	p value
Age range (years)	75-89		90-104		
Sex (female)	284	49.9	87	69.0	< 0.001
Emergency ERCP	400	70.3	108	85.7	< 0.001
Clinical presentation					
Acute cholangitis					
Mild cholangitis	147	25.8	32	25.4	1.0
Moderate cholangitis	165	29.0	46	36.5	0.12
Severe cholangitis	42	7.4	19	15.1	0.010
Biliary pancreatitis	54	9.5	19	15.1	0.091
Obstructive jaundice without cholangitis	35	6.2	2	1.6	0.065
Elevated liver test with normal serum bilirubin and without cholangitis	48	8.4	4	3.2	0.065
asymptomatic CBD stones	78	13.7	4	3.2	0.002
Chronic concomitant diseases					
Hemodialysis	12	2.1	0	0	0.14
Cardiovascular disease	101	17.8	24	19.0	0.83
Cerebrovascular disease	57	10.0	14	11.1	0.84
Liver cirrhosis	6	1.1	1	0.8	1.0
Diabetes mellitus	65	11.4	9	7.1	0.21
≥2 comorbidities	74	13.0	13	10.3	0.50
Antithrombotic drugs	197	34.6	33	26.2	0.086
Peri-ampullary diverticulum	175	30.8	46	36.5	0.25
Diameter of common bile duct [mean, (range)], mm	11.7 (4-30)		13.1(5-25)		< 0.001
Dilated common bile duct (>10 mm)	334	58.7	92	73.0	0.004
Number of stones [mean, (range)]	2.3 (0-20)		2.1 (0-15)		0.57
Multiple stones	228	40.1	53	42.1	0.75
Size of stones [mean, (range)], mm	7.9 (2-25)		9.4 (3-30)		0.077
Large stone (>10 mm)	115	20.2	36	28.6	0.052
Multiple and large stones	67	11.8	23	18.3	0.070
Gallbladder stones	332	58.3	73	57.9	1.0
Post-cholecystectomy	62	10.9	15	11.9	0.87
Performance status (3 or 4)	124	21.8	55	43.7	< 0.001

Table 1. Demographic and Other Characteristics of the Study Population.

ERCP: endoscopic retrograde cholangiopancreatography, CBD: common bile duct

PTGBD [2/695 (0.3%)]. More than 2 modalities were used in 118 (17.0%) patients. CBD stones were detected in 574 of the 695 (82.6%) patients by at least 1 imaging modality; in the remaining 121 patients, a clinical diagnosis of CBD was made. In 628 of the 680 (92.4%) patients who underwent successful cannulation, CBD stones were actually detected during ERCP.

Findings and outcomes of ERCP

ERCP-related findings and outcomes are presented in Table 2. No significant differences were observed between elderly patients 75-89 years of age and elderly patients ≥90 years of age with respect to the proportions of procedures performed by trainee endoscopists, the rate of successful cannulation, pancreatic guidewire-assisted cannulation, pancreatic injections, precut sphincterotomy, EST, EPBD, EPLBD, cannulation time >10 minutes, prophylactic pancreatic stent placement, or procedure time. Complete stone removal was achieved in 540 of the 569 (94.9%) elderly patients 75-89 years of age and in 102 of the 126 (81.0%) elderly patients \geq 90 years of age (p<0.001). In both groups, a permanent biliary stent was successfully placed in all patients with successful cannulation where complete stone removal could not be achieved. No significant between-group differences were observed regarding the use of a mechanical lithotripter, mean number of ERCP sessions per patient required for a successful procedure, and the mean hospital stay duration.

Reasons for incomplete stone removal

The reasons for incomplete stone removal are presented in Table 3. Among patients with incomplete stone removal, significantly more patients \geq 90 years of age were unable to tolerate complete stone removal because of severe medical conditions or a poor performance status or dementia than patients 75-89 years of age.

	Patients aged 75-89 years (n=569)		Patients aged ≥90 years (n=126)			
	n	%	n	%	p value	
Successful cannulation	556	97.7	124	98.4	1.0	
•Complete stone removal	540	94.9	102	81.0	< 0.001	
•Incomplete stone removal	16	2.8	22	17.5	< 0.001	
Unsuccessful cannulation	13	2.3	2	1.6	1.0	
Trainee endoscopist	98	17.2	21	16.7	0.98	
PGW-assist cannulation	113	19.9	29	23.0	0.50	
Pancreatic injections	286	50.3	66	52.4	0.74	
Precut sphincterotomy	31	5.4	6	4.8	0.93	
EST	382	67.1	84	66.7	1.0	
EPBD	76	13.4	16	12.7	0.96	
EPLBD	98	17.2	24	19.0	0.72	
Cannulation time>10 min	171	30.1	37	29.4	0.96	
Mechanical lithotripter	113	19.9	26	20.6	0.94	
Permanent biliary stent placement	16	2.8	22	17.5	< 0.001	
Prophylactic pancreatic stent	98	17.2	25	19.8	0.57	
Procedure time (SD), min	27.6 (15.1)		29.8 (20.0)		0.16	
ERCP attempts for successful procedure [mean (range)]	2.0 (1-7)		1.9 (1-6)		0.13	
Hospital stay (mean), days	13.1		14.7		0.081	

Table 2. ERCP-related Findings and Outcomes in Patients Aged 75-89 and ≥90 Years.

ERCP: endoscopic retrograde cholangiopancreatography, PGW: pancreatic guide-wire, EST: endoscopic sphincterotomy, EPBD: endoscopic papillary balloon dilation, EPLBD: endoscopic papillary large balloon dilation

Table 3.	The Reasons for	Incomplete Stone	Removal in Patients	Aged 75-89 and ≥90 Years.

	Patients aged 75-89 years (n=556)		Patients aged ≥90 years (n=124)		
	n	%	n	%	p value
Severe medical conditions intolerable for stone removal	1	0.2	6	4.8	<0.001
Poor performance status or dementia	12	2.2	14	11.3	< 0.001
Multiple and large stones	3	0.5	2	1.6	0.23

Incidence of post-ERCP complications

Of the 695 patients, 56 (8.1%) experienced post-ERCP complications during hospitalization, including PEP, cholangitis/cholecystitis, bleeding, perforation, pneumonia, and cardiovascular and cerebrovascular events. The incidence of complications among patients 75-89 years of age and patients \geq 90 years of age was 7.7% (44/569) and 9.5% (12/126), respectively. There were no significant differences in the incidences of post-ERCP complications between patients 75-89 years of age and patients \geq 90 years of age (Table 4).

Severity of post-ERCP complications and mortality

The severity of post-ERCP complications and mortality rates are shown in Table 5. There were no significant between-group differences with respect to the severity of post-ERCP complications. The overall mortality rate in our study population was 0.14% (1/695).

Discussion

In the present retrospective study, we compared the safety and efficacy of endoscopic stone removal between elderly patients \geq 90 years of age and elderly patients 75-89 years of age. No significant between-group differences were observed with respect to the incidence of post-ERCP complications. Although there was no significant between-group difference with respect to the rate of use of mechanical lithotripter, the rate of complete stone removal in elderly patients \geq 90 years of age was significantly lower than that in elderly patients 75-89 years of age.

Several studies have assessed the safety and efficacy of endoscopic removal of CBD stones in elderly patients using the cut-off age of 80-85 years. The results showed that the safety and efficacy of endoscopic stone removal in elderly patients is comparable to that in younger patients (5-8). In Japan, patients \geq 90 years of age are defined as the oldestold patients (4), and a few studies with small sample sizes have assessed the efficacy and safety of stone removal using

	Patients aged 75-89 years (n=569)		Patients aged ≥90 years (n=126)			
	n	%	n	%	p value	
Post-ERCP pancreatitis	21	3.7	2	1.6	0.41	
Acute cholangitis/cholecystitis	11	1.9	2	1.6	1.0	
Bleeding	4	0.7	3	2.4	0.12	
Perforation	2	0.4	0	0	1.0	
Pneumonia	3	0.5	3	2.4	0.076	
Heart failure	1	0.2	1	0.8	0.33	
Complete atrioventricular block	1	0.2	0	0	1.0	
Cerebral infarction	0	0	1	0.8	0.18	
Respiratory dysfunction	1	0.2	0	0	1.0	

Table 4. Incidence of Complications Related to ERCP in Patients Aged 75-89 and ≥90 Years.

ERCP: endoscopic retrograde cholangiopancreatography

≥90 Years.			
	Patients aged 75-89 years (n=44)	Patients aged ≥90 years (n=12)	

Table 5. Severity of Post-ERCP Complications in Patients Aged 75-89 and

	(n=44)		(n=12)			
	n	%	n	%	p value	
Mild	23	52.3	5	41.7	0.74	
Moderate to severe	20	45.5	7	58.3	0.64	
Death	1	2.3	0	0	1.0	

ERCP: endoscopic retrograde cholangiopancreatography

ERCP in this population. For example, a study found no significant difference in the incidence of post-ERCP complications between elderly patients ≥ 90 years of age (n=22) and those 70-89 years of age (n=381) [5% (1/22) vs. 7% (26/381), respectively]. However, the rate of duct clearance was lower in elderly patients ≥90 years of age than in those 70-89 years of age (86% vs. 95%, respectively) (9). Another study that included 63 patients ≥90 years of age with pancreatobiliary diseases (including 51 with CBD stones) found no significant difference in the rate of post-ERCP complications between patients ≥90 years of age and those 70-89 years of age [6.3% (4/63) vs. 8.3% (29/350), respectively]. However, the number of ERCP attempts for stone clearance was higher, and the use of mechanical lithotripter was more frequent among patients ≥90 years of age than in those 70-89 years of age (10).

In the present study, there was no significant difference in the incidence of post-ERCP complications between patients 75-89 years of age and those \geq 90 years of age (7.7% and 9.5%, respectively), and the incidence of moderate-to-severe complications was also comparable between the groups (45.5% and 58.3%, respectively). The reasons for the comparable incidence of post-ERCP complications and complication severity in the two patient groups might be patient selection and the selection of appropriate endoscopic strategies. At our institutions, patients who met the criteria for ERCP for choledocholithiasis underwent ERCP. Severe cholangitis was more frequently observed in patients \geq 90 years of age than in those 75-89 years of age. Patients who were unable to tolerate ERCP were treated by alternative methods, such as antibiotics and percutaneous biliary drainage. Alternative methods were therefore more frequently used in patients \geq 90 years of age than in those 75-89 years of age in the present study. Furthermore, permanent stent placement was performed in high-risk patients with a poor performance status or dementia, severe medical conditions, or large and/ or multiple stones that were difficult to remove, based on the endoscopist's decision. Therefore, when performing ERCP, especially in elderly patients \geq 90 years of age, appropriate patient selection and appropriate selection of endoscopic strategies is important.

Although a previous report showed that use of a mechanical lithotripter was more frequent in patients ≥90 years of age (9, 10), no significant between-group difference was observed in the present study. This might be because patients ≥90 years of age with large and/or multiple stones were treated with EPLBD in our study. EPLBD, first reported in 2003, is effective for removing multiple and large CBD stones that are difficult to remove using EPBD or EST alone (14). In previous studies, stone clearance rates for large stones (>12-15 mm) without the use of the mechanical lithotripter were 89-99% in patients treated with EPLBD (14-16). In the present study, EPLBD was performed in patients with multiple and/or large stones. Patients \geq 90 years of age were more likely than those 75-89 years of age to exhibit multiple and/or large stones, although this difference was not statistically significant. This may explain the lack of any significant between-group differences in the frequency of mechanical lithotripter use in the present study.

In the present study, elderly patients ≥ 90 years of age had a more severe medical condition, poorer performance status, and larger stones than those 75-89 years of age; therefore, the rate of stone clearance was significantly lower than in patients 75-89 years of age (81.0% vs. 94.9%, respectively). These findings are in agreement with earlier reports (9). A previous report showed that biliary stent placement for two months resulted in partial or complete resolution of large or multiple stones without any complications (17). For patients in whom complete stone removal is difficult to achieve due to large or multiple stones, regardless of the use of mechanical lithotripter or EPLBD, biliary stent placement at the initial ERCP and subsequent stone removal after two months may be an effective strategy. Long-term biliary stent placement is another alternative strategy for elderly patients with unsuccessful stone clearance. In a prospective study, the patency rates of plastic biliary stent for choledocholithiasis at 6, 12, and 24 months were 94%, 79%, and 58%, respectively (18). In a systematic review, the mean incidence rates of late complications, biliary-related mortality, and nonbiliary-related mortality were 23%, 3.3%, and 20.5%, respectively (19). Long-term biliary stent placement and close follow-up to detect late complications, such as stent obstruction, are viable options for elderly patients with a poor performance status, severe medical conditions, and multiple and/or large stones.

Appropriate sedation is essential for the success of ERCP procedures. However, sedation can cause oxygen desaturation and/or hypotension. Airway obstruction and respiratory depression have been shown to be the most critical risk factors for mortality associated with endoscopic procedures performed under sedation. The incidence rates outside the operating room were two times higher than inside the operating room (20). In the present study, there were no significant between-group differences in cardio-respiratory complications, possibly because the dose of medication for sedation was determined by the patient's age and weight, based on our institutions' protocols. However, one of our patients discontinued ERCP after EST because of oxygen desaturation caused by sedation. Fortunately, this patient underwent complete stone removal a few days later. ERCP should be carried out under careful vital sign monitoring, especially in elderly patients.

Although the incidence of post-ERCP complications in patients \geq 90 years of age was comparable with that in patients 75-89 years of age in this study, a previous study that examined the risk factors for complications of ERCP among patients \geq 85 years of age found that only age \geq 90 years was a significant risk factor for therapeutic ERCP (21). Another study showed that elderly patients \geq 75 years of age tended to experience more severe complications during endoscopic stone removal than patients <75 years of age (22). Therefore, detailed counseling of elderly patients and their

caregivers about the risks of post-ERCP complications is imperative prior to performing ERCP.

Several limitations associated with the present study warrant mention. First, the present study was a retrospective study. Second, one of the participating institutions suffered extensive damage during the Kumamoto earthquake in April 2016. Owing to the disruption caused by the earthquake, the data obtained from that institution pertained only to a 4-year period (April 2012 to April 2016). Third, only patients who met the criteria for ERCP for choledocholithiasis at our institutions were analyzed. We did not determine the proportion of elderly patients 75-89 years of age and ≥90 years of age who were treated by alternative methods (without ERCP), such as antibiotics and percutaneous biliary drainage. Furthermore, permanent stent placement was performed in patients with a poor performance status or dementia, severe medical conditions, or large and/or multiple stones that were difficult to remove, based on the endoscopist's decision. Therefore, because our study population was defined by our institutions' criteria and our endoscopists' decisions, a selection bias likely exists. Fourth, the long-term outcomes of ERCP in elderly patients ≥90 years of age are unclear because the primary outcome of this study was post-ERCP complications during hospitalization.

In conclusion, we found that the incidence of post-ERCP complications during hospitalization in elderly patients \geq 90 years of age was similar to that in elderly patients 75-89 years of age. Although the complete stone removal rate was lower in elderly patients \geq 90 years of age than in those 75-89 years of age, biliary stent placement was successful in all patients with incomplete stone removal. Among elderly patients with choledocholithiasis \geq 90 years of age, ERCP is a safe and effective procedure; however, when performing ERCP in very elderly patients, endoscopists should consider the risks of ERCP based on each patient's medical condition and background and select the appropriate strategy for the patients.

The authors state that they have no Conflict of Interest (COI).

Acknowledgement

We thank the staff involved in therapeutic ERCP for choledocholithiasis at the participating institutions.

References

- United Nations, Department of Economic and Social Affairs, Population Division (2017). World Population Prospects: The 2017 Revision, Key Findings and Advance Tables. ESA/P/WP/248 [Internet]. [cited 2017 Jun. 16]. Available from: https://population.un. org/wpp/Publications/Files/WPP2017_KeyFindings.pdf
- 2. Siegel JH, Kasmin FE. Biliary tract diseases in the elderly: management and outcomes. Gut 41: 433-435, 1997.
- Anderson MA, Fisher L, Jain R, et al. Complications of ERCP. Gastrointest Endosc 75: 467-473, 2012.
- **4.** Ouchi Y, Rakugi H, Arai H, et al. Redefining the elderly as aged 75 years and older: proposal from the Joint Committee of Japan Gerontological Society and the Japan Geriatrics Society. Geriatr

Gerontol Int 17: 1045-1047, 2017.

- **5.** Obana T, Fujita N, Noda Y, et al. Efficacy and safety of therapeutic ERCP for the elderly with choledocholithiasis: comparison with younger patients. Intern Med **49**: 1935-1941, 2010.
- 6. Ito Y, Tsujino T, Yamamoto O, et al. Endoscopic papillary balloon dilation for the management of bile duct stones in patients 85 years of age and older. Gastrointest Endosc 68: 477-482, 2008.
- Iida T, Kaneto H, Wagatsuma K, et al. Efficacy and safety of endoscopic procedures for common bile duct stones in patients aged 85 years or older: a retrospective study. PLoS One 13: e0190665, 2018.
- Kanamori A, Kiriyama S, Tanikawa M, et al. Long- and shortterm outcomes of ERCP for bile duct stones in patients over 80 years old compared to younger patients: a propensity score analysis. Endosc Int Open 4: E83-E90, 2016.
- Sugiyama M, Atomi Y. Endoscopic sphincterotomy for bile duct stones in patients 90 years of age and older. Gastrointest Endosc 52: 187-191, 2000.
- 10. Katsinelos P, Paroutogou G, Kountouras J, Zavos C, Beltsis A, Tzovaras G. Efficacy and safety of therapeutic ERCP in patients 90 years of age and older. Gastrointest Endosc 63: 417-423, 2006.
- Jorgensen J, Kubiliun N, Law JK, et al.; ASGE Training Committee. Endoscopic retrograde cholangiopancreatography (ERCP): core curriculum. Gastrointest Endosc 83: 279-289, 2016.
- 12. Kiriyama S, Kozaka K, Takada T, et al. Tokyo Guidelines 2018: diagnostic criteria and severity grading of acute cholangitis (with videos). J Hepatobiliary Pancreat Sci 25: 17-30, 2018.
- Cotton PB, Eisen GM, Aabakken L, et al. A lexicon for endoscopic adverse events: report of an ASGE workshop. Gastrointest Endosc 71: 446-454, 2010.
- 14. Ersoz G, Tekesin O, Ozutemiz AO, Gunsar F. Biliary sphincterotomy plus dilation with a large balloon for bile duct stones that are

difficult to extract. Gastrointest Endosc 57: 156-159, 2003.

- Maydeo A, Bhandari S. Balloon sphincteroplasty for removing difficult bile duct stones. Endoscopy 39: 958-961, 2007.
- 16. Minami A, Hirose S, Nomoto T, Hayakawa S. Small sphincterotomy combined with papillary dilation with large balloon permits retrieval of large stones without mechanical lithotripsy. World J Gastroenterol 13: 2179-2182, 2007.
- 17. Horiuchi A, Nakayama Y, Kajiyama M, et al. Biliary stenting in the management of large or multiple common bile duct stones. Gastrointest Endosc 71: 1200-1203, 2010.
- 18. Li KW, Zhang XW, Ding J, Chen T, Wang J, Shi WJ. A prospective study of the efficacy of endoscopic biliary stenting on common bile duct stones. J Dig Dis. 10: 328-331, 2009.
- 19. Ang TL, Fock KM, Teo EK, Chua TS, Tan J. An audit of the outcome of long-term biliary stenting in the treatment of common bile duct stones in a general hospital. J Gastroenterol. 41: 765-771, 2006.
- 20. Sharma VK, Nguyen DD, Crowell MD, Lieberman DA, de Garmo P, Fleischer DE. A national study of cardiopulmonary un-planned events after GI endoscopy. Gastrointest Endosc 66: 27-33, 2007.
- 21. Takahashi K, Tsuyuguchi T, Sugiyama H, et al. Risk factors of adverse events in endoscopic retrograde cholangiopancreatography for patients aged ≥85 years. Geriatr Gerontol Int 18: 1038-1045, 2018.
- **22.** Nishikawa T, Tsuyuguchi T, Sakai Y, et al. Old age is associated with increased severity of complications in endoscopic biliary stone removal. Dig Endosc **26**: 569-576, 2014.

The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).

© 2019 The Japanese Society of Internal Medicine Intern Med 58: 2125-2132, 2019